Kezar Life Sciences Stock Today
| KZR Stock | USD 4.12 0.38 8.44% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Kezar Life is selling at 4.12 as of the 5th of April 2025; that is 8.44 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.62. Kezar Life has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 5th of January 2025 and ending today, the 5th of April 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of June 2018 | Category Healthcare | Classification Health Care |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company was incorporated in 2015 and is based in South San Francisco, California. The company has 7.31 M outstanding shares of which 60.45 K shares are now shorted by investors with about 2.21 days to cover. More on Kezar Life Sciences
Moving together with Kezar Stock
| 0.76 | A | Agilent Technologies | PairCorr |
| 0.83 | ME | 23Andme Holding | PairCorr |
| 0.68 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.82 | VANI | Vivani Medical | PairCorr |
Moving against Kezar Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Kezar Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKezar Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kezar Life's financial leverage. It provides some insight into what part of Kezar Life's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kezar Life Sciences (KZR) is traded on NASDAQ Exchange in USA. It is located in 4000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 55 people. Kezar Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 30.1 M. Kezar Life Sciences runs under Biotechnology sector within Health Care industry. The entity has 7.31 M outstanding shares of which 60.45 K shares are now shorted by investors with about 2.21 days to cover.
Kezar Life Sciences has about 306.84 M in cash with (74.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kezar Life Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Kezar Life Sciences is $30.1 Million. Over half of Kezar Life's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Kezar Ownership Details
Kezar Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-12-31 | 100.1 K | |
| Renaissance Technologies Corp | 2024-12-31 | 87.7 K | |
| Qiming U.s. Ventures Management, Llc | 2024-12-31 | 82.9 K | |
| Blackrock Inc | 2024-12-31 | 82.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 66.6 K | |
| Two Sigma Investments Llc | 2024-12-31 | 62 K | |
| Shay Capital Llc | 2024-12-31 | 59.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 52.3 K | |
| Bml Capital Management Llc | 2024-12-31 | 48.7 K | |
| Tang Capital Management Llc | 2024-12-31 | 720 K | |
| Suvretta Capital Management, Llc | 2024-12-31 | 716.8 K |
Kezar Life Historical Income Statement
Kezar Stock Against Markets
Kezar Life Corporate Management
| Joe Tedrick | Vice Resources | Profile | |
| Noreen MD | Chief Officer | Profile | |
| Pattie Chiang | Senior Controller | Profile | |
| Michael Wolfe | Sr Operations | Profile |
Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.